Related Experiment Video
Updated: May 22, 2026
12:27
A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors
Published on: June 8, 2022
Building a better sphingosine kinase-1 inhibitor
1Department of Pharmacology, University of Virginia, Charlottesville, 22908, USA. krl2z@virginia.edu
The Biochemical Journal
|April 27, 2012
Summary
Researchers developed a potent and selective Sphingosine kinase 1 (SphK1) inhibitor. This new chemical tool helps investigate targeting sphingosine 1-phosphate (S1P) synthesis for therapeutic strategies against diseases like cancer and fibrosis.
Area of Science:
- Lipid mediator research
- Immunology
- Drug discovery
Background:
- Sphingosine 1-phosphate (S1P) is a key lipid mediator with critical roles in immune cell trafficking.
- Modulation of S1P signaling, as seen with fingolimod for multiple sclerosis, highlights its therapeutic potential.
- Sphingosine kinases (SphK1 and SphK2) synthesize S1P, and SphK1 is implicated in fibrosis, inflammation, and cancer.
Purpose of the Study:
- To develop and characterize a potent and selective small molecule inhibitor of Sphingosine kinase 1 (SphK1).
- To provide a crucial chemical tool for exploring the therapeutic potential of targeting S1P synthesis.
Main Methods:
- Small molecule inhibitor development
- Biochemical assays to determine potency and selectivity
- Genetic manipulation and mouse models (implied)
Main Results:
- A potent and selective small molecule inhibitor of SphK1 was successfully described.
- This inhibitor serves as a valuable tool for further research.
Conclusions:
- Targeting S1P synthesis via SphK1 inhibition is a potential therapeutic strategy.
- The developed SphK1 inhibitor is essential for validating this approach in various pathological conditions.
